Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study

被引：0
|
作者：
Spinner, C. [1 ]
Stoehr, A. [2 ]
Wong, A. [3 ]
de Wet, J. [4 ]
Zeggagh, J. [5 ]
Hocqueloux, L. [6 ]
van Welzen, B. [7 ]
Heinzkill, M. [8 ]
Sahali, S. [9 ]
Cornejo, A. Torres [10 ]
Ramroth, H. [11 ]
Haubrich, R. [12 ]
Thorpe, D. [13 ]
Kim, C. [14 ]
机构：
[1] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Munich, Germany
[2] IFI Studien & Projekte GmbH, Zentrum Infektiol, Hamburg, Germany
[3] Univ Saskatchewan, Dept Med, Regina, SK, Canada
[4] Spectrum Hlth, Vancouver, BC, Canada
[5] Hop St Louis, AP HP, Serv Malad Infect, Paris, France
[6] CHR Orleans, Serv Malad Infect & Trop, Orleans, France
[7] Univ Med Ctr, Internal Med & Infect Dis, Utrecht, Netherlands
[8] Gilead Sci GmbH, HIV Med Affairs, Munich, Germany
[9] Gilead Sci, HIV Med Affairs, Paris, France
[10] Gilead Sci Netherlands BV, HIV Med Affairs, Amsterdam, Netherlands
[11] Gilead Sci Ltd, Pharmacovigilance & Epidemiol, London, England
[12] Gilead Sci Inc, Med Affairs Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[13] Gilead Sci Europe Ltd, HIV Med Affairs, London, England
[14] Gilead Sci Canada Inc, HIV Med Affairs, Mississauga, ON, Canada
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P046
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [31] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naı<spacing diaeresis>ve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study
    Tseng, Yu-Ting
    Yang, Chia-Jui
    Kim, Yeon-Sook
    Choi, Jun Yong
    Wong, Chen Seong
    Lee, Kuan-Yeh
    Lee, Jeong-a
    Chang, Jack
    Harrison, Rebecca
    Marongiu, Andrea
    Lee, Sun Hee
    Hung, Chien-Ching
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (05) : 760 - 770
  • [32] Switching from a second-line ritonavir-boosted protease inhibitor-based regimen to bictegravir/emtricitabine/ tenofovir alafenamide: results of a randomized clinical trial
    Pierre, S.
    Marc, J. B.
    Homeus, F.
    Bernadin, G. R.
    Trevisi, L.
    Jean, E.
    Dumont, E.
    Sundaresan, S.
    Rivera, V.
    Israelski, D.
    Collins, S. E.
    Pape, J. W.
    Liautaud, B.
    Severe, P.
    Sax, P. E.
    Koenig, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 26 - 26
  • [33] Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study
    Cano-Smith, J.
    Delgado-Hierro, A.
    Valencia, E.
    Ramos, L.
    Busca, C.
    Mican, R.
    Martin-Carbonero, L.
    Montes, M. L.
    De Miguel, R.
    Montejano, R.
    Moreno, V.
    Perez-Sadaba, F.
    Perez-Rambla, C.
    Molina, R.
    Gonzalez-Garcia, J.
    Bernardino, J. I.
    HIV MEDICINE, 2023, 24 : 411 - 412
  • [34] Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study
    Esser, S.
    Trottier, B.
    Antinori, A.
    Hila, E.
    Antela, A.
    Tigen, E. Tukenmez
    Boffito, M.
    Lambert, J. S.
    van Welzen, B. J.
    Mack, F.
    Schreiber, S.
    Cassidy, T.
    Harrison, R.
    Saifi, T.
    Sabranski, M.
    Vassallo, M.
    HIV MEDICINE, 2023, 24 : 412 - 414
  • [35] Comparison of dolutegravir plus Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Yang, Xiaoyan
    Ma, Shujing
    Kong, Linghong
    Song, Chunli
    Song, Yebing
    Ren, Tingting
    Long, Hai
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (10) : 877 - 884
  • [36] Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
    Rolle, Charlotte-Paige
    Castano, Jamie
    Nguyen, Vu
    Hinestrosa, Federico
    Dejesus, Edwin
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
  • [37] Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide
    Andreatta, K.
    Acosta, R.
    D'Antoni, M. L.
    Liu, H.
    Chang, S.
    Martin, R.
    Collins, S.
    Martin, H.
    White, K. L.
    HIV MEDICINE, 2021, 22 : 62 - 62
  • [38] Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial
    Rossetti, Barbara
    Ferrara, Micol
    Taramasso, Lucia
    Bai, Francesca
    Lombardi, Francesca
    Ciccarelli, Nicoletta
    Durante, Miriam
    Alladio, Francesca
    Bonazza, Federica
    Rancan, Ilaria
    Montagnani, Francesca
    Di Biagio, Antonio
    Monforte, Antonella d'Arminio
    Zazzi, Maurizio
    Fabbiani, Massimiliano
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (01) : 293 - 304
  • [39] Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Kiertiburanakul, Sasisopin
    Ratanasuwan, Winai
    Siripassorn, Krittaecho
    Supparatpinyo, Khuanchai
    Martin, Hal
    Wang, Hui
    Wong, TinHung
    Wang, Hsiu Yin
    HIV MEDICINE, 2023, 24 (03) : 290 - 300
  • [40] Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055
    Bachelard, Antoine
    Isernia, Valentina
    Charpentier, Charlotte
    Benalycherif, Aida
    Mora, Marion
    Donadille, Cecile
    Duvivier, Claudine
    Lacombe, Karine
    Mouhebb, Mayssam El
    Spire, Bruno
    Landman, Roland
    Descamps, Diane
    Peytavin, Gilles
    Assoumou, Lambert
    Ghosn, Jade
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (03) : 769 - 778
12345